Cabozantinib Dose Skipping as an Alternative to Dose Reductions

The goal of this study is to determine if an alternative cabozantinib dosing regimens results in a similar drug exposure compared to the standard regimens in patients with metastatic renal cell carcinoma (mRCC). All dosages of cabozantinib (20 ,40, 60mg) have the same price, and cabozantinib is eliminated very slowly by the body. This means that using fewer tablets could potentially lead to cost savings, while remaining equally effective. The main questions it aims to answer are: * Is the drug exposure from our experimental regimens similar to the standard dosing regimens? * Do the experimen

Trial Details

NCT ID
NCT07077161
Phase
PHASE2
Sponsor
dr. Tom van der Hulle
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Cabozantinib
Locations (sample)
  • Leiden, South Holland, Netherlands|52.15833,4.49306

Key Eligibility Criteria

  • Willing and able to provide informed consent;
  • Aged 18 years or older;
  • Histologically confirmed advanced renal cell carcinoma;
  • At least 4 weeks on a stable dosage of cabozantinib of 40 mg or 20 mg once daily as single-agent treatment or in combination with nivolumab;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →